LOX-1 is a novel marker for peripheral artery disease in patients with type 2 diabetes

Objective. The aim of this study was to investigate whether serum soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1), which mediates initiation and progression of atherosclerosis in endothelial cells, could be a novel marker for peripheral artery disease (PAD) in patients with type 2 diabetes. Methods. We evaluated relationships of serum sLOX-1 to ankle-brachial index (ABI) and examined the association of serum sLOX-1 with PAD in 410 patients with type 2 diabetes. Results. Serum sLOX-1 was inversely correlated with ABI (r=-0.197, P<0.0001). Stepwise regression analysis demonstrated that serum sLOX-1 (beta=-0.168, F=5.571, P<0.05) was independently associated with ABI, and multiple logistic regression analysis demonstrated that serum sLOX-1 (16.254(1.237-213.651), P=0.0339) was independently associated with PAD. Conclusions. Serum sLOX-1 is associated with ABI and it could be a novel marker for PAD in patients with type 2 diabetes. (C) 2013 Elsevier Inc. All rights reserved.